Emerging insights underscore a need to look beyond seizures alone
Phase 1 trial of azer-cel reports good preliminary safety and efficacy
Physical, occupational and speech therapists will provide state-of-the-art outpatient care
Inconsistent regulation and limited toxicology tests present diagnostic and treatment challenges
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Milestone case report expands understanding of infectious risks for those on immunomodulatory therapies
Advanced technologies are changing expectations about what’s possible
A rare opportunity to design for speed, care coordination, recovery and continuous monitoring
Multidisciplinary, proactive approach also improved discharge outcomes
Phase 1 Breakfree-2 trial reports good safety and efficacy at week 26
Inflammatory protein eotaxin-1 may be a marker of future cognitive decline
Advertisement
Advertisement